Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Rituximab in Untreated Follicular Lymphoma
NCT03789240Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in follicular lymphoma (FL), sponsored by National Cancer Institute. Started Aug 2019; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03789240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789240.